Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Adoption and Expansion of Telehealth Solutions_Profile_Social Worker.pdf Adoption and Expansion of Telehealth Solutions Multidisciplinary Profile: Social Worker The Association of Community Cancer Centers (ACCC) conducted a brief interview with Sarah Everette, MSSW, an oncology social worker at Baptist Health Louisville in Kentucky, and Karen Kayser, PhD, MSW, professor emeritus …
“Today, pharmacists have practice authorities that go way beyond dispensing,” writes Scott Knoer, MS, PharmD, FASHP, in recognition of American Pharmacists Month in October. The CEO of the American Pharmacists Association, Dr. Knoer writes in his blog, “We’re diagnosing, preventing, and treating COVID-19; helping Americans stay up-to-date on all their routine vaccinations; and delivering care in new …
Utilizing biomarker testing can add a valuable perspective when determining optimal treatment strategies and engaging patients with metastatic colorectal cancer in shared decision-making.
While we talk to patients about insurance coverage and answer their related questions throughout the year, the health insurance Marketplace and Medicare open enrollment seasons provide the best opportunity to educate patients about their insurance options.
Due in no small part to global awareness efforts and transformative technological advances in breast cancer treatment, there has been a 40% decline in breast cancer deaths in the past 30 years. Nevertheless, current statistics remain sobering. An estimated 284,200 individuals in the U.S. will be diagnosed with invasive breast cancer in 2021, and approximately 44,130 people will die from the …
Data Entry Sheet Subject Instrument: Demographic and Clinical Features Sex Race Primary Insurance Type Aggregate Clinical Stage NSCLC Histology Instrument: Molecular Testing Did the clinician request Molecular Testing for this patient? (tissue testing, not including PDL1) Did this patient receive Molecular Testing? (tissue testing, not including PDL1) If Yes, was it a single …
1 Association of Community Cance r Cente rs Improving the Timeliness of Biomarker Testing by Using Liquid Biopsy When Tissue Samples are Insufficient for Testing Problem Statement Root Causes Biomarker testing may be delayed when tissue samples are inadequate for testing. This may lead to delays in definite treatment planning for patients who have actionable molecular biomarkers …
1 Association of Community Cancer Centers Standardize and Streamline the Process Around Ordering Lung Cancer Biomarker Tests Problem Statement Root Causes To reduce variability and improve efficiencies, there is a need to standardize and streamline the process around ordering lung cancer biomarker tests ● Oncologists have different attitudes and preferences around: when to …
1 Association of Community Cancer Centers Increase Referrals for Smoking Cessation Problem Statement Root Causes Patients with advanced lung cancer are not receiving referrals for smoking cessation • Patients may not express interest in smoking cessation • Lack of awareness about local smoking cessation resources • Oncologists may be reluctant to refer patients …
Full Baseline Data Entry Sheet Notes of clarification are shown in this row. Please also report if a patient is dually eligible for Medicare and Medicaid. Please convert the staging variables to Version 8 (as accurately as possible) Here you can note if the patient was not originally staged as version 8 This includes PD-L1 testing and genomic alterations If tested with a standard …
1 Association of Community Cancer Centers Improving the Identification and Management of irAEs (immune-related adverse events) Problem Statement Root Causes There is a need for more proactive symptom identification, assessment, monitoring, and management • This is especially true for patients treated with immunotherapy • Patients treated with oral agents are also difficult …
1 Association of Community Cancer Centers Increase the Identification of Patients Who may be Eligible for Clinical Trials Problem Statement Root Causes Patients with advanced lung cancer are not being referred for clinical trial opportunities • Patients may have misconceptions about clinical trials • Lack of awareness about open clinical trials • Oncologists may be reluctant …
1 Association of Community Cancer Centers Reducing Preventable Emergency Department (ED) Visits Problem Statement Root Causes Certain patients may be at high risk for ED visits and/or hospitalization • Some patients have multiple comorbidities (e.g., COPD, need for supplemental oxygen, etc.) • There is no formal process for risk stratification …
1 Association of Community Cancer Centers Improving the Process of Obtaining and Entering NSCLC Biomarker Test Results into the EHR Problem Statement Root Causes The process of obtaining and entering NSCLC biomarker test results (NGS lab) into the EHR is inefficient and may lead to delays in treatment • The current process is manual and trigged by an email that is …
1 Association of Community Cancer Centers Increasing Referrals to Palliative Care and Hospice Problem Statement Root Causes Patients with advanced lung cancer are not receiving referrals to palliative care and hospice in a timely fashion There is a need for better symptom management; earlier referrals to hospice; better care planning at the end of life • Patients may …
Genetic counselors—as members of the cancer care team—can help patients better understand their cancer diagnosis, make informed treatment decisions, and navigate the financial costs of testing.
FOSTERING EXCELLENCE IN CARE AND OUTCOMES IN PATIENTS WITH STAGE III/IV NSCLC Develop and implement a pathology-driven reflex testing process so that pathologists have the information they need to order biomarker testing at the time of diagnosis Initiate a liquid biopsy order at the time of diagnosis if it appears that the tissue is likely to be insufficient for testing Introduction Founded …
Quality Improvement Key Takeaways There remain numerous ongoing opportunities to increase testing rates in patients with advanced NSCLC. To identify the root causes that contribute to suboptimal testing, begin by mapping the process and reviewing how tissue and blood testing is ordered, tracked, and reported. When tissue samples are insufficient for testing, utilize liquid biopsy (circulating …
FOSTERING EXCELLENCE IN CARE AND OUTCOMES IN PATIENTS WITH STAGE III/IV NSCLC The team included representatives from medical oncology, process improvement, pathology, information technology, billing, and administration. The team developed a process map (see decision tree figure below and on back side) and identified three potential laboratory vendors that would perform the biomarker …
FOSTERING EXCELLENCE IN CARE AND OUTCOMES IN PATIENTS WITH STAGE III/IV NSCLC FOSTERING EXCELLENCE IN CARE AND OUTCOMES IN PATIENTS WITH STAGE III/IV NSCLC Southern Ohio Medical Center Portsmouth, Ohio Assign a nurse navigator to track, enter, and communicate positive biomarker test results Proactively coordinate appointments for patients who have positive test results so that targeted …